Effects of the selective phosphodiesterase type 5 inhibitor sildenafil citrate [sildenafil] on exercise capacity and vascular function in hypertensive subjects

Trial Profile

Effects of the selective phosphodiesterase type 5 inhibitor sildenafil citrate [sildenafil] on exercise capacity and vascular function in hypertensive subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2010

At a glance

  • Drugs Sildenafil (Primary) ; Hydralazine
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Apr 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 09 Apr 2010 Actual patient number (30) added as reported by ClinicalTrials.gov.
    • 09 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top